Generex Biotechnology Announces Record & Payment Dates for 20:1 Stock Dividend
Generex Biotechnology Corporation (www.generex.com)
(OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote)
today announced that the Record Date for the determination of the holders of the Company’s common stock entitled to participate in
the Company’s previously announced 20:1 common stock dividend will be Monday, November 5, 2018. The dividend Payment Date
will be Tuesday, November 13, 2018.
The stock dividend will result in 20 shares of common stock paid on November 13, 2018 for every one share of common stock owned
as of the close of business on November 5, 2018.
About Generex Biotechnology Corporation
Generex is a strategic, diversified healthcare holdings company with offerings in a variety of services, diagnostics, medical
devices, and pharmaceutical development.
The Company’s direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and
additional health-related services to greatly improve the patient experience in receiving care.
On the provider side, Generex’s management services remove administrative burdens in multiple provider settings, including
private practice and hospital, allowing doctors to devote more time to patient care.
Revenue from the Company’s subsidiaries will support clinical advancement of its wholly owned therapeutic products with a focus
in immunotherapeutics based on stimulating critical members of the immune response, known as T helper cells, and its proprietary
buccal administration of insulin.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may
contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should,"
"subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may
cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from
time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with
any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid
placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for
forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Biotechnology Corporation
Joseph Moscato, 646-599-6222
or
Todd Falls, 800-391-6755 Extension 222
investor@generex.com
or
Russo Partners
Investor / Media Contacts:
Alex Fudukidis, 646-942-5632
alex.fudukidis@russopartnersllc.com
or
Caroline Cunningham, 212-845-4292
Caroline.Cunningham@russopartnersllc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181031005673/en/